$XBI $93.25 | +2.8%
Covid Updates
$RDHL -5.5% RedHill Biopharma's Oral Opaganib Reduces Mortality by 70% Given on Top of Remdesivir and Corticosteroids in Severe COVID-19. source
$ADMP +5.8% Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19. source
Pipeline Updates
$SGMO +2.9% Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease source
$ISEE +8.0% Iveric Bio Announces New Post-Hoc Analyses of Zimura® from GATHER1 Clinical Trial to Be Presented at Angiogenesis, Exudation, and Degeneration 2022. source
$NGM +5.1% NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. source
$ACXP +0.3% Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases. source
$ENDP +2.0% Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles. source
$QURE +1.1% uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease. source
$EVLO +1.2% Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial. source
Business Updates
$VERA +7.7% Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock source
Posted by FS/JM
Comments